Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Replicor Inc.
Antios Says Its Novel Hepatitis B Mechanism Can Help Toward Functional Cure
First-in-class active-site polymerase inhibitor yields Phase Ib/IIa data showing suppression of HBV DNA. It also demonstrated a good safety profile with normalization of liver enzymes.
Gilead Turns Back To Virology With $1.4bn MYR Acquisition
MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.
Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis
The latest developments in one of the US FDA's favorite pathways.
Pipeline Watch: Phase III Updates For Eravacycline, Opdivo And Keytruda
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.